🫀Fellow @MayoAZCVFellows 🌵☀️| @DartmouthHealth @OUWB @ASUEngineering | ☕ Coffee in hand, heart in collaboration & patient-centered care
Scottsdale, AZ
Joined May 2020
- Tweets422
- Following353
- Followers258
- Likes1.9K
Girish Pathangey retweeted
Hot off the press: jacc.org/doi/10.1016/j.jacad…
Simultaneous publication @AHAScience
@JACCJournals
TAVR outcomes in patients with HCM
@sahmIbrah @M_H_Abdelnabi @ramziw_ @alsidawimd
Girish Pathangey retweeted
AHA 2026 Mayo Clinic Arizona Abstracts and complex cases.
@sahmIbrah @M_H_Abdelnabi @momina_md @kwanleemd @MayoAZCVFellows @MayoClinicCV
#AHA26 #ScientificSessions26 #Cardiology
Grand Rounds by Dr. Ikari, sharing his journey developing the Ikari catheter. Loved the heart-shaped catheter slide at the end! ❤️ @MayoAZCVFellows
Such a great time at #TCT2026 in San Diego! ☀️ 🫀 Really proud of my co-fellows for sharing their amazing work. Couldn’t ask for a better group to grow alongside! @MayoAZCVFellows @M_H_Abdelnabi @Mo_Allam90 @HA_Noureldine @sahmIbrah @DrMCTan @AyaElalfy @TCTMD @crfheart
Girish Pathangey retweeted
Congrats on @PhilGenereuxMD and PROGRESS
investigators on their seminal work NEJM Group on RCT of Mod AS with at risk factors to surveillance vs @Edwards_TAVR SAPIEN 3 #TAVR, presented at LBCT #TCT2026 @crfheart @TCTMD
Open label trial. ⬇️☠️or HF event at 2y (p=0.02). No diff in ☠️. Effect driven by HF event. Delayed conversion to AVR still has same KCCQ-12 benefit after initial decline. More vigilant screening and follow up are key to capture this group of pts esp those who are symptomatic, which was the predominant reason for enrollment in this trial.
Now published in @NEJM
nejm.org/doi/full/10.1056/NE…
Girish Pathangey retweeted
#TCT 2026 complex cases and science by @MayoAZCVFellows and @MayoClinicCV. @crfheart #Cardiology #interventionalcardiology
@ChadiAyoub1 @kwanleemd @M_H_Abdelnabi @GPathangey @sahmIbrah @DrMCTan
Girish Pathangey retweeted
Presented at #TCT2026:
In a randomized trial, CCTA-guided PCI with structured preprocedural planning and intraprocedural guidance was noninferior to intravascular ultrasound–guided PCI with respect to target-vessel failure at 12 months. Full P4 trial results: nej.md/48jfVly
@crfheart
ALT A graph from the Original Article "Coronary CT Angiography versus Intravascular Ultrasound Guidance for PCI." The trial name, P4, is in parentheses after the title. The graph shows the cumulative incidence of target-vessel failure (primary end point), defined as a composite of death from cardiac causes, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization, at 12 months. The trial results are being presented at the Transcatheter Cardiovascular Therapeutics 2026 Conference. The logo of the New England Journal of Medicine is at the bottom.
Girish Pathangey retweeted
✈️ Off to #TCT2026
Excited to represent @MayoClinicCV as our team @MayoAZCVFellows will be presenting several research projects at the conference.
Always a pleasure to present our work, connect with colleagues, and learn about the new advances in Interventional cardiology!
Girish Pathangey retweeted
Day 1 #TCT2026 @crfheart complex cases, breaking science and good discussions.
#interventionalcardiology
#Cardiology
Girish Pathangey retweeted
We are excited to welcome Dr. Deepa Mandale as our newest faculty member!
After completing her CV training @MayoClinic, she recently completed her level III Imaging and Advanced Echocardiography fellowship at @HeartUCSF.
She will add fire power to our growing non-invasive section and interventional structural programs. @Sidsinecho @psorajja
Girish Pathangey retweeted
I created LearnCoronary (learncoronary.com), an interactive tool designed to help general cardiology fellows and other early-career learners better understand coronary angiography and the spatial relationships between different angiographic views.
#cardiotwitter @OpenAI
Girish Pathangey retweeted
Checkout our latest: SGLT2 inhibitors after TEER in T2DM are associated with lower 1-year mortality and fewer major adverse kidney events—without a significant difference in MACE or AKI. A signal worth exploring further.
doi.org/10.2459/JCM.00000000…
@MayoClinicCV
@MayoAZCVFellows
Keep up the innovative work, @samarthrawal, making time spent with patients a priority over paperwork.
One cool aspect of Osler Prerounds is that, since all the data is stored where you choose, tools like @ChatGPT w/ EMR access can also read/write to Prerounds as wanted!
In this way, Prerounds goes from being just a personal clinician dashboard to a window that can harness clinical AI in a highly customizable and intuitive way.
Ie, clinicians can ask ChatGPT to define reminders, follow-ups, update labs conditionally, etc, and auto-update their Osler Prerounds dashboards!
this is also ai-agnostic: works with ChatGPT/Codex, Claude Code, local models, or whatever is approved by your local institution’s PHI policies!
1
2
373
Girish Pathangey retweeted
One cool aspect of Osler Prerounds is that, since all the data is stored where you choose, tools like @ChatGPT w/ EMR access can also read/write to Prerounds as wanted!
In this way, Prerounds goes from being just a personal clinician dashboard to a window that can harness clinical AI in a highly customizable and intuitive way.
Ie, clinicians can ask ChatGPT to define reminders, follow-ups, update labs conditionally, etc, and auto-update their Osler Prerounds dashboards!
this is also ai-agnostic: works with ChatGPT/Codex, Claude Code, local models, or whatever is approved by your local institution’s PHI policies!
Hi clinician friends - I'm really excited to release Osler Prerounds! Prerounds is a tool I built for hospital medicine, to serve as a "command center" to think, plan, and track everything during busy inpatient service.
I've been using it daily on inpatient medicine service, and it has been extremely useful in helping me better reason about, and stay on top of, patient management.
Some useful features:
- quickly store and track evolving patient data across your entire service
- TODO tracking across all patients + timed reminders for tasks
- export to PDF/printout to take with you during rounds
- all data is stored 100% locally, with nothing leaving your computer!
Available now, for free! any feedback welcome :)
Girish Pathangey retweeted
New publication: We evaluated AI-derived coronary calcium scoring (AI-CAC) from routine chest CT as a prognostic tool in 1,873 patients on ICI.
Higher CAC burden = higher 1-yr MI risk.
@DigitalHealthJ @ChadiAyoub1 @MayoAZCVFellows
journals.sagepub.com/doi/10.…
#CardioTwitter #AI
Lots of excitement and potential for high-risk PCI. Looking forward to seeing more data and, eventually, whether this tech can be expanded to cardiogenic shock cohort.
A novel low-profile (10F) percutaneous LV support device with up to 5.5 L/min demonstrates favorable performance and device-related safety in an early high-risk PCI feasibility study. The SUPPORT I Study. @azeemlatib @Kandzari ahajrnls.org/3QVIyzX
Girish Pathangey retweeted
Checkout our latest publications “Cannabidiol in Cardiovascular Disease: A Review of Current Evidence and Future Directions”
sciencedirect.com/science/ar…
@GPathangey
@ramziw_
@ChadiAyoub1
@MayoClinicCV
@MayoAZCVFellows
Girish Pathangey retweeted
Honored and excited to join this @ACCinTouch committee as a fellow-in-training and learn from the outstanding group of EP faculty! 🫀
@MayoAZCVFellows @MayoClinic
Girish Pathangey retweeted
Honored to serve as a Member of the Fellows in Training (FIT) Section Leadership Council 🫀 @ACCinTouch
Grateful for the support @MayoClinicCV
@MayoAZCVFellows
#ACCFIT
#AHAFIT
#cardiotwitter
Girish Pathangey retweeted
#mdpijcm
#LatestPaper Sharing
#GraphicalAbstract
Beyond Lipids and Platelets: A Review of Anti-Inflammatory Strategies in Secondary Prevention of #AcuteCoronarySyndromes
👉mdpi.com/3579950
👥@GPathangey @M_H_Abdelnabi
🏬@MayoClinic
@MediPharma_MDPI
